Related Experiment Videos
Risk factors for hyphema after trabeculectomy with mitomycin C
Sachi Kojima1, Masaru Inatani, Kohei Shobayashi
1*Department of Ophthalmology and Visual Science, Graduate School of Medical Sciences, Kumamoto University, Kumamoto †Department of Ophthalmology, Faculty of Medical Science, University of Fukui, Fukui, Japan.
Journal of Glaucoma
|February 5, 2013
Summary
Neovascular glaucoma (NVG) and anticoagulant use are key risk factors for hyphema after trabeculectomy with mitomycin C (MMC). Preoperative intravitreal bevacizumab may reduce this risk in NVG patients.
Area of Science:
- Ophthalmology
- Glaucoma Surgery
- Vascular Complications
Background:
- Hyphema is a potential complication following glaucoma surgery.
- Identifying risk factors for hyphema is crucial for patient management and surgical planning.
Purpose of the Study:
- To identify risk factors associated with hyphema after trabeculectomy with mitomycin C (MMC).
Main Methods:
- Retrospective evaluation of 420 patients undergoing trabeculectomy with MMC.
- Logistic multivariable analysis was used to determine risk factors for hyphema.
- Subgroup analysis was performed for patients with neovascular glaucoma (NVG).
Main Results:
- Hyphema occurred in 24.8% of patients.
- Neovascular glaucoma (NVG) and anticoagulant/antiplatelet medication were significant risk factors.
- In NVG patients, anterior chamber neovascularization and anticoagulant use increased risk, while intravitreal bevacizumab reduced it.
Conclusions:
- NVG and anticoagulant/antiplatelet medication are independent risk factors for hyphema post-trabeculectomy with MMC.
- In NVG, neovascularization and anticoagulants increase risk, but intravitreal bevacizumab can mitigate this.
- These findings aid in risk stratification and treatment decisions for glaucoma patients.
Related Concept Videos
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
01:22Microbiome of the Eye
The human eye has a specialized microbiota that reflects its unique anatomical and immunological environment. This low-biomass microbial community predominantly colonizes the conjunctiva and eyelid margins, playing a vital role in ocular surface homeostasis and defense. Despite its proximity to the richly colonized facial skin, the ocular surface maintains a distinct microbial profile due to continuous mechanical and biochemical defense mechanisms.The conjunctival surface hosts fewer microbial...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...